Basic Information
| LncRNA/CircRNA Name | lncRNA-LET |
| Synonyms | NPTN-IT1, lncRNA-LET |
| Region | GRCh38_15:73567012-73569294 |
| Ensemble | ENSG00000281183 |
| Refseq | NR_103844 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, RIP, western blot etc. |
| Sample | BC tissues, cell lines (T24, 5637, J82, SW780, BIU87, ScaBER and UMUC3) |
| Expression Pattern | down-regulated |
| Function Description | LET was the only lncRNA that was downregulated more than 2 folds in GEM-treated xenografts derived from both T24 and 5637 cells. The array results were further validated in these cell lines treated with or without GEM. reduced lncRNA-LET increased the NF90 protein stability, which in turn repressed biogenesis of miR-145 and subsequently resulted in accumulation of CSCs evidenced by the elevated levels of stemness markers HMGA2 and KLF4. UBC patients which displayed lower expression levels of lncRNA-LET and miR-145 had a reduced survival rate, whereas TGFB1 expression level did not show significant difference in clinical outcome. |
| Pubmed ID | 28839463 |
| Year | 2017 |
| Title | TGFB1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer |
External Links
| Links for lncRNA-LET | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |